Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stasix
- Development stage
- Preclinical
- Lead developer
- Entegrion
- Administration
- Intravenous
01
Overview
Stasix is a freeze-dried, long-shelf-life replacement for blood platelets. It is intended for battlefield use to control severe bleeding in trauma patients. The drug is being developed by Entegrion, which received a $7.8 million grant from the U.S. Department of Defense to fund its work on this product.
Beyond the preview
Go deeper on Stasix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stasix.